Q2 2024 Sarepta Therapeutics Inc Earnings Call Transcript
Key Points
- Sarepta Therapeutics Inc (SRPT) achieved net product revenue of approximately $361 million in Q2 2024, a 51% increase over the same quarter last year.
- ELEVIDYS, their gene therapy for Duchenne muscular dystrophy, received broad FDA approval in June 2024, making it available to over 80% of Duchenne patients in the U.S.
- The company has become profitable and cash flow positive as of this quarter.
- Sarepta Therapeutics Inc (SRPT) anticipates strong revenue growth in Q4 2024 and projects 2025 net product revenue to be between $2.9 billion and $3.1 billion.
- The company has a robust pipeline and has established itself as a leader in RNA and gene therapy for rare diseases.
- The process from enrollment form to infusion for ELEVIDYS typically takes between three and five months, which may moderate revenue growth in the near term.
- There is a potential for modest cannibalization of their PMO franchise by ELEVIDYS in the coming quarters.
- The company expects to record approximately $55 million to $65 million in additional research and development expenses due to the termination of a development and supply agreement.
- There are concerns about the capacity of treatment centers to handle the unprecedented demand for ELEVIDYS, leading to potential long wait times for patients.
- The company faces risks and uncertainties that could materially and adversely affect its business, results of operations, and trading prices for its common stock.
Good day and thank you for standing by. Welcome to the Sarepta Therapeutics second-quarter 2024 financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your speaker for today, Mary Jenkins, Associate Director, Investor Relations and Corporate Communications. Please go ahead.
Thank you, Lisa, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the second-quarter 2024. The press release is available on our website at sarepta.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon.
Joining us on the call today are Doug Ingram, Ian Estepan, Dallan Murray, and Dr. Louise Rodino-Klapac. After our formal remarks, we'll open the call for Q&A.
I'd like to note that during the call, we will be making a number of forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
